Ingredion Announces Strategic Investments in India Expanding into High-Value Pharmaceutical Ingredients

Published on: 

Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.

Ingredion announced on March 24, 2023 that it has completed two strategic investments in India to expand into high-value pharmaceutical applications. The company acquired Amishi Drugs & Chemicals (AD&C), a manufacturer of superdisintegrants, lubricants, and viscosifiers, and secured a majority position in Mannitab Pharma Specialties, a supplier of specialty sugars to the pharmaceutical industry.

The investments complement Ingredion’s portfolio of starch, mannitol, and dextrose product offerings, as well as expand Mannitab’s manufacturing capacity for spray-dried mannitol for direct compression. Ingredion’s portfolio also now includes binders, fillers, superdisintegrants, lubricants, gelatin replacers for softgels, viscosofiers, encapsulation materials, and parenteral-grade dextrose.

“These investments are part of our strategy to expand our specialty pharmaceutical product portfolio to better serve our customers and diversify into high-value nonfood adjacencies,” said Jim Zallie, Ingredion’s president and CEO, in a company press release.


“Ingredion looks forward to partnering with pharma and nutraceutical formulators and helping them meet regulatory challenges, progress drug development, and identify emerging trends,” added Rana Kayal, global director for pharma and nutraceuticals, in the release.

Source: Ingredion